Relationship Between Cardiovascular Disease Risk Factors and Quality of Life in Patients with Metabolic-Associated Fatty Liver Disease

被引:0
|
作者
Jamali, Raika [1 ,2 ]
Veisi, Soroush [1 ]
Jamali, Arsia [3 ]
Yaseri, Mehdi [4 ]
机构
[1] Univ Tehran Med Sci, Sina Hosp, Res Dev Ctr, Tehran, Iran
[2] Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, Iran
[3] Eisenhower Med Ctr, Dept Internal Med, Rancho Mirage, CA USA
[4] Univ Tehran Med Sci, Dept Epidemiol & Biostat, Tehran, Iran
关键词
Quality of Life; Cardiovascular Disease Risk Factors; Metabolic-Associated Fatty Liver Disease; Fatty Liver; PROFILE;
D O I
10.5812/hepatmon-124229
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Metabolic-associated fatty liver disease (MAFLD) is a common cause of liver-related mortality and morbidity worldwide. However, there is a paucity of literature on the relationship between cardiovascular disease (CVD) risk factors and quality of life (QoL) in patients with MAFLD. Objectives: This study aimed to examine the association between QoL and CVD risk factors in an Iranian MAFLD population. Methods: This study was conducted on MAFLD patients, referred to the gastroenterology clinic of a general hospital from September 2017 until September 2018. The QoL and Framingham Risk Score (FRS) were determined using the WHOQOL-BREF questionnaire and an online web calculator, respectively. A hierarchical multiple linear regression model was developed to evaluate the association between QoL and FRS after adjusting for the sociodemographic characteristics. Results: This study was performed on 200 participants. All domains of QoL were associated with older age, hypertension, smoking, diabetes mellitus, higher systolic blood pressure, and lower high-density lipoprotein levels in the univariate regression analysis (P < 0.05 for all). Meanwhile, FRS was adversely correlated with the total QoL score (correlation coefficient: -0.49; 95% CI: -0.61, -0.35; P < 0.001). After adjusting for the sociodemographic variables, the results of the hierarchical multiple linear regression model showed that age, smoking, diabetes mellitus, hypertension, and FRS were correlated with the overall QoL score (P < 0.05 for all). Hypertension was the main predictor of the total QoL score (B = -5.51, 95% CI: -7.18, -3.68; P < 0.05). A higher FRS was inversely associated with the physical domain of QoL (B 0.05, 95% CI: -0.09, -0.01; P < 0.05), the environment domain of QoL (B = -0.04, 95% CI: -0.09, -0.01; P < 0.05), and the total score of QoL (B = -0.04, 95% CI: -0.08, -0.02; P < 0.05). Conclusions: According to the results of this study, a higher risk of developing CVD may reduce QoL in patients with MAFLD. Hypertension, diabetes mellitus, and smoking were the key predictive determinants of QoL in this population. Further studies are suggested to determine if modification of the mentioned risk factors can improve QoL in MAFLD patients.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Metabolic-associated fatty liver disease and the risk of cardiovascular disease
    Zhang, Pengwei
    Dong, Xianhui
    Zhang, Wei
    Wang, Shiyin
    Chen, Chen
    Tang, Jiake
    You, Yao
    Hu, Siqi
    Zhang, Shenghui
    Wang, Chunyi
    Wen, Wen
    Zhou, Mengyun
    Tan, Tao
    Qi, Guanming
    Li, Li
    Wang, Mingwei
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2023, 47 (01)
  • [2] Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach
    Drozdz, Karolina
    Nabrdalik, Katarzyna
    Kwiendacz, Hanna
    Hendel, Mirela
    Olejarz, Anna
    Tomasik, Andrzej
    Bartman, Wojciech
    Nalepa, Jakub
    Gumprecht, Janusz
    Lip, Gregory Y. H.
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [3] Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach
    Karolina Drożdż
    Katarzyna Nabrdalik
    Hanna Kwiendacz
    Mirela Hendel
    Anna Olejarz
    Andrzej Tomasik
    Wojciech Bartman
    Jakub Nalepa
    Janusz Gumprecht
    Gregory Y. H. Lip
    Cardiovascular Diabetology, 21
  • [4] Cardiovascular disease in metabolic-associated fatty liver disease
    Adams, Leon A.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2023, 30 (02) : 81 - 86
  • [5] Smoking Increases the Risk of Hepatocellular Carcinoma and Cardiovascular Disease in Patients with Metabolic-Associated Fatty Liver Disease
    Yoo, Jeong-Ju
    Park, Man Young
    Cho, Eun Ju
    Yu, Su Jong
    Kim, Sang Gyune
    Kim, Yoon Jun
    Kim, Young Seok
    Yoon, Jung-Hwan
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (09)
  • [6] Association between maternal factors and risk of metabolic-associated fatty liver disease in offspring
    De Ruyter, Hanna
    Aitokari, Linnea
    Jaaskelainen, Tiina
    Huhtala, Heini
    Laivuori, Hannele
    Kurppa, Kalle
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2023, 102 : 3 - 3
  • [7] IMPACT OF SARCOPENIA AND ADVANCED FIBROSIS ON CARDIOVASCULAR RISK IN PATIENTS WITH METABOLIC-ASSOCIATED FATTY LIVER DISEASE
    Lee, Jae Chang
    Kim, Kye Whon
    Kang, Min Kyu
    Lee, Yu Rim
    Jang, Se Young
    Kweon, Young Oh
    Tak, Won Young
    Park, Soo Young
    Park, Jung Gil
    HEPATOLOGY, 2022, 76 : S809 - S809
  • [8] Sex-linked cardiovascular risk in patients with metabolic-associated fatty liver disease (MAFLD)
    Montesano, A.
    Lanza, E.
    Di Ciaula, A.
    Khalil, M.
    Galerati, I.
    Abdallah, H.
    Belfiore, A.
    Bonfrate, L.
    Portincasa, P.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2023, 53
  • [9] The dynamic patterns of metabolic-associated fatty liver disease and its severity and risk of cardiovascular disease
    Cui, Haozhe
    Chen, Yongliang
    Zhao, Zhiming
    HEPATOLOGY INTERNATIONAL, 2025, 19 (01) : 131 - 142
  • [10] Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome
    Sinn, Dong Hyun
    Kang, Danbee
    Choi, Sung Chul
    Hong, Yun Soo
    Zhao, Di
    Guallar, Eliseo
    Park, Yewan
    Cho, Juhee
    Gwak, Geum-Youn
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (07) : 1873 - +